Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) Net Margin (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Net Margin for 6 consecutive years, with 70.93% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Margin fell 8770.0% year-over-year to 70.93%, compared with a TTM value of 33.02% through Dec 2025, down 3002.0%, and an annual FY2025 reading of 33.02%, down 3002.0% over the prior year.
  • Net Margin was 70.93% for Q4 2025 at Cytek Biosciences, down from 10.48% in the prior quarter.
  • Across five years, Net Margin topped out at 16.78% in Q4 2024 and bottomed at 70.93% in Q4 2025.
  • Average Net Margin over 5 years is 8.18%, with a median of 5.76% recorded in 2022.
  • The sharpest move saw Net Margin surged 1528bps in 2024, then plummeted -8770bps in 2025.
  • Year by year, Net Margin stood at 1.01% in 2021, then surged by 625bps to 7.3% in 2022, then rose by 29bps to 9.45% in 2023, then surged by 78bps to 16.78% in 2024, then tumbled by -523bps to 70.93% in 2025.
  • Business Quant data shows Net Margin for CTKB at 70.93% in Q4 2025, 10.48% in Q3 2025, and 12.24% in Q2 2025.